Key Highlights
- Perrigo climbed on Wednesday while the health care sector slumped.
- No Earnings release, deal or analyst action was tied to the stock.
- Health care was the second-worst S&P 500 sector.
- Health insurers led the decline after a Medicare Advantage audit proposal.
A gain against the trend
Perrigo (NYSE:PRGO) climbed on Wednesday, placing the stock among the gainers on the New York Stock Exchange.
No company-specific news was identified for Perrigo during the session. There was no earnings release, deal or analyst action tied to the stock. The gain came as the broader health care sector slumped, making the move stand out.
A rough day for health care
Health care was the second-worst sector in the S&P 500 on Wednesday, behind only energy. The sell-off was led by health insurers, which fell for a second straight day after the Centers for Medicare and Medicaid Services proposed a rule that would extend Medicare Advantage audit and overpayment lookbacks to payment year 2018.
UnitedHealth Group (NYSE:UNH) was the worst performer in the Dow and Humana (NYSE:HUM) the worst in the S&P 500. Elevance Health (NYSE:ELV), Centene (NYSE:CNC) and CVS Health (NYSE:CVS) also fell sharply. CMS Administrator Dr. Mehmet Oz framed the proposal as a way to "crush fraud, waste, and abuse." The rule is not final, and comments are due January 19, 2027.
Drugmakers also slipped. Merck (NYSE:MRK), Eli Lilly (NYSE:LLY), Johnson and Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) all moved lower with the sector.
Why Perrigo is different
Perrigo's Business has little direct connection to Medicare Advantage. The company focuses on consumer self-care products sold without a prescription, which may help explain why it did not follow insurers lower.
Perrigo makes over-the-counter medicines and health products, many of them sold as store brands by large retailers and pharmacies. Its portfolio spans categories such as allergy, cough and cold remedies, pain relief, digestive health, oral care and infant formula, alongside some branded products. Because many of its customers are retailers, its fortunes are tied to consumer spending on everyday health items rather than to insurer reimbursement.
That profile places Perrigo between health care and consumer staples. Consumer staples slipped slightly in the S&P 500 on Wednesday, while consumer discretionary was the best-performing sector, and TJX (NYSE:TJX) and Target (NYSE:TGT) rose after strong results.
The broader market
The major indexes were mixed. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and its longest losing streak since June. The Dow fell 561.25 points to 50,198.17, while the Nasdaq Composite rose 101.50 points to 24,429.88 and the Russell 2000 gained 12.44 points to 2,714.31.
Rates remained in focus. Minutes from the Federal Reserve's October meeting showed almost all participants judged that further increases in the federal funds rate "would likely be appropriate," and Fed Governor Christopher Waller said, "I'm very, very concerned about inflation. It's kind of headed in the wrong direction, and it's spreading out."
Sentiment was cautious overall. A widely followed Fear and Greed index stood at 25, in "Extreme Fear" territory, while the VIX Volatility index eased to about 24.6 after touching 26.26.
Perrigo's Defensive Profile Meets a Rate-Sensitive Market
For Perrigo, the next Quarterly Report will be the main company-specific event, with investors focused on sales trends in its consumer health categories, margins and progress on its business plans. Retailer Demand for store-brand products could also be in focus.
Health care headlines will stay in view as debate continues over the CMS proposal. On the macro calendar, Thursday brings weekly jobless claims, the Philadelphia Fed survey and Walmart (NASDAQ:WMT) earnings before the open, a read on retail demand. The Fed's next policy meeting is December 8 and 9.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...